Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages

Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population...

Full description

Saved in:
Bibliographic Details
Published in:The Milbank quarterly 2004-01, Vol.82 (4), p.661-687
Main Authors: KRAVITZ, RICHARD L., DUAN, NAIHUA, BRASLOW, JOEL
Format: Article
Language:English
Subjects:
Adverse effects
Clinical trials
Drug Approval - legislation & jurisprudence
Evidence based medicine
Experimentation
genomics
Health care
Health outcomes
Heterogeneity
Humans
Medical practice
Medical research
Original
Policy Making
Population characteristics
Practice Patterns, Physicians
Randomized controlled trials
Randomized Controlled Trials as Topic
Research design
Research methodology
Sample size
Side effects
Sociology
Sociology of health and medicine
Statistics
Strokes
Treatment Outcome
United States
United States Food and Drug Administration
USA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13
cites cdi_FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13
container_end_page 687
container_issue 4
container_start_page 661
container_title The Milbank quarterly
container_volume 82
creator KRAVITZ, RICHARD L.
DUAN, NAIHUA
BRASLOW, JOEL
description Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.
doi_str_mv 10.1111/j.0887-378X.2004.00327.x
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2690188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4149087</jstor_id><sourcerecordid>4149087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13</originalsourceid><addsrcrecordid>eNqNkV1v0zAUhiMEYt3gHyAUIbGrpdiOv3IB0laVbVI3xDQE4saynZPWXZoMO-3af49Dqw64Ad_4433eo-PzJkmK0RDH9W4-RFKKLBfy25AgRIcI5UQM10-SAaZcZgih4mky2EMHyWEI8_iK8lw-Tw4wYwUrKB8k38crV0JjITvTAcr0CkpnXQMn6QV04NspNOC6TdpW6a0H3S2g6dJxVYHtwkmqmzLtZhCldmlqSB9cN0tPV-D1FMKL5Fml6wAvd_tR8uXj-HZ0kU0-nV-OTieZ5YKKTDNKiDAFpZgZjYgpLGem4BY0VCx-zlhGcmNKSQwFbHS8lSWRotRlqQHnR8mHbd37pVlAaWOHXtfq3ruF9hvVaqf-VBo3U9N2pQgvEJYyFjjeFfDtjyWETi1csFDXuoF2GRQXmHPM-D9BJjAWkuURfPMXOG-XvolTUIRIjvMC99XkFrK-DcFDtW8ZI9XHrOaqT1D1Cao-ZvUrZrWO1te_f_nRuMs1Am93gA5W15XXjXXhkRNx5ELQyL3fcg-uhs1_N6CuLief4yn6X23989C1fu-nmBZI9nK2lV3oYL2Xtb-LQ80FU1-vz9XNzRm5ZiOuZP4TTQnc4w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228613916</pqid></control><display><type>article</type><title>Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages</title><source>EBSCOhost Business Source Ultimate</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>International Bibliography of the Social Sciences (IBSS)</source><source>Wiley Online Library</source><source>PubMed Central（OA）</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>PAIS Index</source><creator>KRAVITZ, RICHARD L. ; DUAN, NAIHUA ; BRASLOW, JOEL</creator><creatorcontrib>KRAVITZ, RICHARD L. ; DUAN, NAIHUA ; BRASLOW, JOEL</creatorcontrib><description>Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.</description><identifier>ISSN: 0887-378X</identifier><identifier>EISSN: 1468-0009</identifier><identifier>DOI: 10.1111/j.0887-378X.2004.00327.x</identifier><identifier>PMID: 15595946</identifier><identifier>CODEN: MIQUES</identifier><language>eng</language><publisher>350 Main Street , Malden , MA 02148 , USA , and 9600 Garsington Road , Oxford OX4 2DQ , UK: Blackwell Publishing, Inc</publisher><subject>Adverse effects ; Clinical trials ; Drug Approval - legislation &amp; jurisprudence ; Evidence based medicine ; Experimentation ; genomics ; Health care ; Health outcomes ; Heterogeneity ; Humans ; Medical practice ; Medical research ; Original ; Policy Making ; Population characteristics ; Practice Patterns, Physicians ; Randomized controlled trials ; Randomized Controlled Trials as Topic ; Research design ; Research methodology ; Sample size ; Side effects ; Sociology ; Sociology of health and medicine ; Statistics ; Strokes ; Treatment Outcome ; United States ; United States Food and Drug Administration ; USA</subject><ispartof>The Milbank quarterly, 2004-01, Vol.82 (4), p.661-687</ispartof><rights>Copyright 2004 Milbank Memorial Fund</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Blackwell Publishers Inc. 2004</rights><rights>2004 Milbank Memorial Fund</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13</citedby><cites>FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.0887-378X.2004.00327.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.0887-378X.2004.00327.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27899,27957,27958,31034,31035,33258,50923,51032,53827,53829,58593,58826</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17227774$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15595946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KRAVITZ, RICHARD L.</creatorcontrib><creatorcontrib>DUAN, NAIHUA</creatorcontrib><creatorcontrib>BRASLOW, JOEL</creatorcontrib><title>Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages</title><title>The Milbank quarterly</title><addtitle>Milbank Q</addtitle><description>Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.</description><subject>Adverse effects</subject><subject>Clinical trials</subject><subject>Drug Approval - legislation &amp; jurisprudence</subject><subject>Evidence based medicine</subject><subject>Experimentation</subject><subject>genomics</subject><subject>Health care</subject><subject>Health outcomes</subject><subject>Heterogeneity</subject><subject>Humans</subject><subject>Medical practice</subject><subject>Medical research</subject><subject>Original</subject><subject>Policy Making</subject><subject>Population characteristics</subject><subject>Practice Patterns, Physicians</subject><subject>Randomized controlled trials</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research design</subject><subject>Research methodology</subject><subject>Sample size</subject><subject>Side effects</subject><subject>Sociology</subject><subject>Sociology of health and medicine</subject><subject>Statistics</subject><subject>Strokes</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><subject>USA</subject><issn>0887-378X</issn><issn>1468-0009</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>7TQ</sourceid><sourceid>8BJ</sourceid><recordid>eNqNkV1v0zAUhiMEYt3gHyAUIbGrpdiOv3IB0laVbVI3xDQE4saynZPWXZoMO-3af49Dqw64Ad_4433eo-PzJkmK0RDH9W4-RFKKLBfy25AgRIcI5UQM10-SAaZcZgih4mky2EMHyWEI8_iK8lw-Tw4wYwUrKB8k38crV0JjITvTAcr0CkpnXQMn6QV04NspNOC6TdpW6a0H3S2g6dJxVYHtwkmqmzLtZhCldmlqSB9cN0tPV-D1FMKL5Fml6wAvd_tR8uXj-HZ0kU0-nV-OTieZ5YKKTDNKiDAFpZgZjYgpLGem4BY0VCx-zlhGcmNKSQwFbHS8lSWRotRlqQHnR8mHbd37pVlAaWOHXtfq3ruF9hvVaqf-VBo3U9N2pQgvEJYyFjjeFfDtjyWETi1csFDXuoF2GRQXmHPM-D9BJjAWkuURfPMXOG-XvolTUIRIjvMC99XkFrK-DcFDtW8ZI9XHrOaqT1D1Cao-ZvUrZrWO1te_f_nRuMs1Am93gA5W15XXjXXhkRNx5ELQyL3fcg-uhs1_N6CuLief4yn6X23989C1fu-nmBZI9nK2lV3oYL2Xtb-LQ80FU1-vz9XNzRm5ZiOuZP4TTQnc4w</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>KRAVITZ, RICHARD L.</creator><creator>DUAN, NAIHUA</creator><creator>BRASLOW, JOEL</creator><general>Blackwell Publishing, Inc</general><general>Blackwell Publishers</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TQ</scope><scope>8BJ</scope><scope>DHY</scope><scope>DON</scope><scope>FQK</scope><scope>JBE</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20040101</creationdate><title>Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages</title><author>KRAVITZ, RICHARD L. ; DUAN, NAIHUA ; BRASLOW, JOEL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adverse effects</topic><topic>Clinical trials</topic><topic>Drug Approval - legislation &amp; jurisprudence</topic><topic>Evidence based medicine</topic><topic>Experimentation</topic><topic>genomics</topic><topic>Health care</topic><topic>Health outcomes</topic><topic>Heterogeneity</topic><topic>Humans</topic><topic>Medical practice</topic><topic>Medical research</topic><topic>Original</topic><topic>Policy Making</topic><topic>Population characteristics</topic><topic>Practice Patterns, Physicians</topic><topic>Randomized controlled trials</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research design</topic><topic>Research methodology</topic><topic>Sample size</topic><topic>Side effects</topic><topic>Sociology</topic><topic>Sociology of health and medicine</topic><topic>Statistics</topic><topic>Strokes</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><topic>USA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KRAVITZ, RICHARD L.</creatorcontrib><creatorcontrib>DUAN, NAIHUA</creatorcontrib><creatorcontrib>BRASLOW, JOEL</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>PAIS Index</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Milbank quarterly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KRAVITZ, RICHARD L.</au><au>DUAN, NAIHUA</au><au>BRASLOW, JOEL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages</atitle><jtitle>The Milbank quarterly</jtitle><addtitle>Milbank Q</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>82</volume><issue>4</issue><spage>661</spage><epage>687</epage><pages>661-687</pages><issn>0887-378X</issn><eissn>1468-0009</eissn><coden>MIQUES</coden><notes>ArticleID:MILQ327</notes><notes>ark:/67375/WNG-RRB2N5C6-8</notes><notes>istex:C1FF7A8D6FA60B1CA11F11202F69C3490F642770</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.</abstract><cop>350 Main Street , Malden , MA 02148 , USA , and 9600 Garsington Road , Oxford OX4 2DQ , UK</cop><pub>Blackwell Publishing, Inc</pub><pmid>15595946</pmid><doi>10.1111/j.0887-378X.2004.00327.x</doi><tpages>27</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-378X
ispartof The Milbank quarterly, 2004-01, Vol.82 (4), p.661-687
issn 0887-378X
1468-0009
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2690188
source EBSCOhost Business Source Ultimate; Applied Social Sciences Index & Abstracts (ASSIA); International Bibliography of the Social Sciences (IBSS); Wiley Online Library; PubMed Central（OA）; JSTOR Archival Journals and Primary Sources Collection; PAIS Index
subjects Adverse effects
Clinical trials
Drug Approval - legislation & jurisprudence
Evidence based medicine
Experimentation
genomics
Health care
Health outcomes
Heterogeneity
Humans
Medical practice
Medical research
Original
Policy Making
Population characteristics
Practice Patterns, Physicians
Randomized controlled trials
Randomized Controlled Trials as Topic
Research design
Research methodology
Sample size
Side effects
Sociology
Sociology of health and medicine
Statistics
Strokes
Treatment Outcome
United States
United States Food and Drug Administration
USA
title Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T14%3A57%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence-Based%20Medicine,%20Heterogeneity%20of%20Treatment%20Effects,%20and%20the%20Trouble%20with%20Averages&rft.jtitle=The%20Milbank%20quarterly&rft.au=KRAVITZ,%20RICHARD%20L.&rft.date=2004-01-01&rft.volume=82&rft.issue=4&rft.spage=661&rft.epage=687&rft.pages=661-687&rft.issn=0887-378X&rft.eissn=1468-0009&rft.coden=MIQUES&rft_id=info:doi/10.1111/j.0887-378X.2004.00327.x&rft_dat=%3Cjstor_pubme%3E4149087%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c6747-a54227b94415ba02b9c65b96ceaef5004bc523bbd82b4e1ba523dd287daddae13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=228613916&rft_id=info:pmid/15595946&rft_jstor_id=4149087&rfr_iscdi=true